Filing Details
- Accession Number:
- 0000950170-25-010575
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-01-29 17:16:00
- Reporting Period:
- 2025-01-27
- Accepted Time:
- 2025-01-29 17:16:00
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1936258 | Newamsterdam Pharma Co N.v. | NAMS | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1699022 | F Douglas Kling | C/O Newamsterdam Pharma Company N.v. Gooimeer 2-35 Naarden P7 1411 DC | Chief Operating Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Acquisiton | 2025-01-27 | 104,174 | $0.00 | 148,174 | No | 4 | M | Direct | |
| Ordinary Shares | Disposition | 2025-01-27 | 80,359 | $0.00 | 67,815 | No | 4 | S | Direct | |
| Ordinary Shares | Disposition | 2025-01-27 | 23,815 | $0.00 | 44,000 | No | 4 | S | Direct | |
| Ordinary Shares | Acquisiton | 2025-01-28 | 25,385 | $0.00 | 69,385 | No | 4 | M | Direct | |
| Ordinary Shares | Disposition | 2025-01-28 | 20,237 | $0.00 | 49,148 | No | 4 | S | Direct | |
| Ordinary Shares | Disposition | 2025-01-28 | 5,148 | $0.00 | 44,000 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Ordinary Shares | Option (right to buy) | Disposition | 2025-01-27 | 104,174 | $0.00 | 104,174 | $0.00 |
| Ordinary Shares | Option (right to buy) | Disposition | 2025-01-28 | 25,385 | $0.00 | 25,385 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 321,971 | 2031-07-06 | No | 4 | M | Direct | |
| 296,586 | 2031-07-06 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
- The exercise price of the option is 1.16392 euros.
- These shares were sold in multiple transactions at prices ranging from $22.46 per share to $23.45 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
- These shares were sold in multiple transactions at prices ranging from $23.46 per share to $23.70 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
- These shares were sold in multiple transactions at prices ranging from $20.92 per share to $21.91 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
- These shares were sold in multiple transactions at prices ranging from $21.93 per share to $22.39 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
- The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021, which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 121,754 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on March 31, 2022, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
Billionaire Hedge Funds
